NVAX — Novavax, Inc.

Summary of Novavax Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $1.1 billion for the full year 2025, a 65% increase year-over-year; Q4 revenue was $147 million, up 67% compared to Q4 2024.
• Non-GAAP Adjusted Total Revenue: $1.1 billion, exceeding guidance by approximately $50 million, driven by Nuvaxovid sales and royalties.
• Income: Positive net income reported for both Q4 and the full year.
• Cash Position: Ended 2025 with $857 million in cash and accounts receivables; additional $80 million in nondilutive cash expected in Q1 2026.
• Cost Reductions: Combined R&D and SG&A expenses were reduced by 42% in Q4 and 53% for the full year.

2. Strategic Updates and Business Highlights:

• Transitioned from a COVID-focused organization to a broader strategy emphasizing partnerships and R&D innovation.
• New partnership with Pfizer for Matrix-M could yield billions in revenue through milestones and royalties.
• Continued success with existing partnerships, including Sanofi and Takeda, with significant market share gains for Nuvaxovid in Japan.
• Focus on expanding the utility of Matrix technology, including potential new formulations and adjuvants for oncology and infectious diseases.

3. Forward Guidance and Outlook:

• 2026 Revenue Framework: Expected adjusted total revenue of $230 million to $270 million, with significant contributions from Nuvaxovid sales and royalties.
• Cost Guidance: Anticipated combined R&D and SG&A expenses of $325 million in 2026, decreasing to $225 million in 2027, and $200 million or below by 2028.
• R&D Pipeline: Plans to advance at least one early-stage asset into clinical trials by 2027, focusing on C. diff, shingles, and RSV.

4. Bad News, Challenges, or Points of Concern:

• The macro and regulatory environment for vaccine companies remains uncertain, posing potential risks.
• Dependence on the successful commercialization of Nuvaxovid by Sanofi, with the first full season of sales expected in 2026.
• Potential delays in tech transfer activities to Sanofi due to their decision to move operations to a U.S. facility, which could impact timelines but not cash flow.

5. Notable Q&A Insights:

• Sanofi Partnership: Executives expressed confidence in the partnership despite upcoming leadership changes at Sanofi, emphasizing strong ongoing collaboration.
• Market Dynamics: The success of Nuvaxovid in the upcoming COVID season is tied to effective contracting and marketing strategies by Sanofi.
• Pipeline Prioritization: R&D efforts are focused on addressing unmet medical needs, with no specific prioritization disclosed for the early pipeline assets, though all are advancing.
• Matrix Technology: There is significant interest from partners in Matrix-M, with ongoing discussions about expanding its applications beyond vaccines to oncology.
• Long COVID Data: Existing literature suggests vaccinated individuals have a lower risk of developing long COVID, which may differentiate Nuvaxovid from mRNA vaccines.

Overall, Novavax is optimistic about its future, driven by strategic partnerships and a diversified R&D pipeline, despite facing regulatory uncertainties and the challenges of transitioning to a broader business model.